# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce reiterates Assembly Biosciences (NASDAQ:ASMB) with a Neutral.
– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interi...
Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(1.66) per share which beat the analyst consensus estimate of ...
HC Wainwright & Co. analyst Ed Arce reiterates Assembly Biosciences (NASDAQ:ASMB) with a Neutral.
Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(1.74) per share which beat the analyst consensus estimate of ...
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Cal...